WHAT IS CLAIMED IS:

1. A mixed carrier, multivalent pneumococcal conjugate composition, comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein the protein carrier is CRM_{197} or tetanus toxoid, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM_{197}, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5.

2. The mixed carrier, multivalent pneumococcal conjugate composition of claim 1, wherein the capsular polysaccharides from serotypes 1 and 5 are conjugated to tetanus toxoid, and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F are conjugated to CRM_{197}.

3. The mixed carrier, multivalent pneumococcal conjugate composition of claim 1, wherein the capsular polysaccharides from serotypes 1 and 3 are conjugated to tetanus toxoid, and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F are conjugated to CRM_{197}.

4. The mixed carrier, multivalent pneumococcal conjugate composition of claim 1, wherein the capsular polysaccharides from serotypes 3 and 5 are conjugated to tetanus toxoid, and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F are conjugated to CRM_{197}.

5. The mixed carrier, multivalent pneumococcal conjugate composition of claim 1, further comprising an adjuvant.

6. The mixed carrier, multivalent pneumococcal conjugate composition of claim 5, wherein the adjuvant is an aluminum-based adjuvant.

7. The mixed carrier, multivalent pneumococcal conjugate composition of claim 6, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

8. The mixed carrier, multivalent pneumococcal conjugate composition of claim 7, wherein the adjuvant is aluminum phosphate.

9. A vaccine comprising the mixed carrier, multivalent pneumococcal conjugate composition of claim 1 and a pharmaceutically acceptable excipient.

10. The mixed carrier, multivalent pneumococcal conjugate composition of claim 1 for use in prophylaxis of *Streptococcus pneumoniae* infection or disease in a subject.

11. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 10, wherein the subject is a human who is at least 50 years old and the disease is pneumonia or invasive pneumococcal disease (IPD).

12. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 10, wherein the subject is a human who is at least 6 weeks old and the disease is pneumonia, invasive pneumococcal disease (IPD), or acute otitis media (AOM).

13. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 12, wherein the subject is 6 weeks to 5 years of age, 2 to 15 months of age, or 6 to 17 years of age.

14. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 10, wherein the subject is a human.

15. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 10, wherein the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is to be administered by intramuscular injection.

16. The mixed carrier, multivalent pneumococcal conjugate composition for use of claim 10, wherein the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is to be administered as part of an immunization series.

17. The vaccine of claim 9, wherein the vaccine is formulated as a single 0.5 ml dose comprising 2 µg to 4 µg of each capsular polysaccharide except the capsular polysaccharide of serotype 6B, and 4 µg to 5 µg of capsular polysaccharide from serotype 6B.

18. The vaccine of claim 17, wherein the vaccine is formulated as a single 0.5 ml dose comprising about 2.2 µg of each capsular polysaccharide except the capsular polysaccharide of serotype 6B, and about 4.4 µg of capsular polysaccharide from serotype 6B.

19. The vaccine of claim 17, further comprising an adjuvant.

20. The vaccine of claim 19, wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.